DGAP-Adhoc

Adhoc: MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma

DGAP-Ad-hoc: MorphoSys AG / Key word(s): Miscellaneous Adhoc: MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma 21-Jul-2017 / 17:56 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, July 21, 2017

Adhoc: MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma

Phase II Trial of Investigational Anetumab Ravtansine Did Not Meet Primary Endpoint in Patients With Advanced Pleural Mesothelioma

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its partner Bayer AG has reported that a phase 2 clinical study examining anetumab ravtansine as monotherapy in patients with recurrent malignant pleural mesothelioma did not meet the primary endpoint of progression-free survival. Anetumab ravtansine is an antibody-drug conjugate (ADC) directed against mesothelin, comprising an antibody made using MorphoSys's HuCAL technology.

Bayer reported further that, anetumab ravtansine is currently being investigated, as monotherapy and in combination, in additional studies, including a Phase Ib multi-indication study in six different types of advanced solid tumors, as well as a Phase Ib combination-study in patients with recurrent platinum-resistant ovarian cancer. According to Bayer, based on the available data, Bayer remains committed to further evaluating the utility and safety of anetumab ravtansine across multiple tumor types with significant unmet medical need.

There is no change to MorphoSys's financial guidance for Fiscal Year 2017.

End of ad hoc announcement

 

About anetumab ravtansine

Anetumab ravtansine is an antibody-drug conjugate (ADC) that specifically targets mesothelin, a surface marker protein overexpressed in many cancers. After binding to mesothelin, anetumab ravtansine is taken up inside the tumor cells, where degrading enzymes release cytotoxic DM4, a maytansinoid tubulin inhibitor, which induces cell cycle arrest and apoptosis in dividing cells. Anetumab ravtansine comprises an antibody made using MorphoSys's HuCAL technology.